Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden

Lupus. 2019 Jul;28(8):954-960. doi: 10.1177/0961203319856988. Epub 2019 Jun 20.

Abstract

Background: Blood pressure visit-to-visit variability is a novel risk factor for deleterious long-term cardiac and renal outcomes in the general population. We hypothesized that patients with systemic lupus erythematosus (SLE) have greater blood pressure visit-to-visit variability than control subjects and that blood pressure visit-to-visit variability is associated with a higher comorbidity burden.

Methods: We studied 899 patients with SLE and 4172 matched controls using de-identified electronic health records from an academic medical center. We compared blood pressure visit-to-visit variability measures in patients with SLE and control subjects and examined the association between blood pressure visit-to-visit variability and patients' characteristics.

Results: Patients with SLE had higher systolic blood pressure visit-to-visit variability 9.7% (7.8-11.8%) than the control group 9.2% (7.4-11.2%), P < 0.001 by coefficient of variation. Additional measures of systolic blood pressure visit-to-visit variability (i.e. standard deviation, average real variation, successive variation and maximum measure-to-measure change) were also significantly higher in patients with SLE than in control subjects. In patients with SLE, blood pressure visit-to-visit variability correlated significantly with age, creatinine, CRP, triglyceride concentrations and the Charlson comorbidity score (all P < 0.05). Hydroxychloroquine use was associated with reduced blood pressure visit-to-visit variability (P < 0.001), whereas the use of antihypertensives, cyclophosphamide, mycophenolate mofetil and corticosteroids was associated with increased blood pressure visit-to-visit variability (P < 0.05).

Conclusion: Patients with SLE had higher blood pressure visit-to-visit variability than controls, and this increased blood pressure visit-to-visit variability was associated with greater Charlson comorbidity scores, several clinical characteristics and immunosuppressant medications. In particular, hydroxychloroquine prescription was associated with lower blood pressure visit-to-visit variability.

Keywords: Systemic lupus erythematosus; cardiovascular disease; renal lupus.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Blood Pressure / drug effects
  • Case-Control Studies
  • Comorbidity*
  • Cyclophosphamide / therapeutic use
  • Databases, Factual
  • Female
  • Humans
  • Hydroxychloroquine / therapeutic use*
  • Hypertension / drug therapy
  • Hypertension / epidemiology*
  • Inflammation / complications*
  • Logistic Models
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / epidemiology*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Mycophenolic Acid / therapeutic use
  • Risk Factors
  • Severity of Illness Index

Substances

  • Adrenal Cortex Hormones
  • Hydroxychloroquine
  • Cyclophosphamide
  • Mycophenolic Acid